Sort
48,018 grants matching “immunotherapy”
CD4+ T cell response to food
$553,342Marc K. Jenkins · University Of Minnesota · R01 · FY2025 · AI
Metabolic barriers to T cell activation in clear cell renal cell carcinoma
$553,322Jeffrey C Rathmell · Vanderbilt University Medical Center · R01 · FY2023 · CA
Light Microscopy Core
$553,318James Sellers · National Heart, Lung, And Blood Institute · Z01 · FY2008 · HL
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma
$553,260Steven W. Dow · Colorado State University · U01 · FY2020 · CA
Phase 1/2 trial of PEP-CMV + nivolumab for newly diagnosed diffuse midline glioma/high-grade glioma and recurrent diffuse midline glioma/high-grade glioma, medulloblastoma, and ependymoma (PRiME II)
$553,167Eric Thompson · Washington University · R01 · FY2025 · CA
Combating melanoma resistance by targeting ABL1/2
$553,135Rina Plattner · University Of Kentucky · R01 · FY2024 · CA
Training Program in Basic Cancer Research
$553,094Wistar Institute · T32 · FY2001 · CA
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers
$553,091Xiaoguang Margaret Liu · Ohio State University · R01 · FY2024 · CA
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment
$553,079Peixuan Guo · Ohio State University · U01 · FY2016 · CA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer
$553,074Kevin Finnbar Staveleyo'carroll · University Of Missouri-Columbia · R01 · FY2021 · CA
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
$553,064Andre Elias Nel · University Of California Los Angeles · R01 · FY2020 · CA
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
$553,064Andre Elias Nel · University Of California Los Angeles · R01 · FY2021 · CA
Immune reconstitution in SIV infected macaques
$553,013University Of Texas Sw Med Ctr/Dallas · R01 · FY2004 · AI
Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment
$552,945Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors
$552,945Randolph J. Noelle · Dartmouth College · R01 · FY2019 · CA
Modified HER-2 Tumor Antigens for Vaccination in Cancer
$552,881Mark J. Mamula · L2 Diagnostics, Llc · R42 · FY2006 · CA
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial
$552,880Lei Zheng · Johns Hopkins University · R01 · FY2023 · CA
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy
$552,877Xue-Zhong Yu · Medical College Of Wisconsin · R01 · FY2022 · CA
Metabolic Impacts of Type II Interferon Signals in Obesity
$552,838Sean Hartig · Baylor College Of Medicine · R01 · FY2022 · DK
Project 1
$552,743David J Odde · University Of Minnesota · P01 · FY2022 · CA
Project 1
$552,743David J Odde · University Of Minnesota · P01 · FY2023 · CA
ANTIIDIOTYPE THERAPY OF HUMAN B CELL MALIGNANCY
$552,663Stanford University · R37 · FY2002 · CA
Mechanisms of Murine Tumor Eradication by Immunotherapy
$552,612Philip D Greenberg · University Of Washington · R01 · FY2010 · CA
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome
$552,594Lajos Pusztai · Yale University · R01 · FY2017 · CA
Novel interventions for gammaherpesvirus infection and AIDS-Related Malignancies
$552,560Laurie T Krug · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA